Compare Abeona Therapeutics Inc (ABEO) vs Snowflake Inc (SNOW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Snowflake Inc — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Snowflake Inc trades at $258.74 (market cap $91.07B). The key difference: Snowflake Inc is far larger — about 243.9× Abeona Therapeutics Inc's market cap. Which is the better fit depends on your goals.
| ABEO | SNOW | |
|---|---|---|
Market Cap | $373.32M | $91.07B |
Sector | Health | Technology |
52-Week High | $7.23 | $280.16 |
52-Week Low | $4.17 | $121.11 |
Enterprise Value | $228.22M | $90.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
SNOW trades at $262.74, up 1.0% today, with a bullish technical outlook from moving averages and strong analyst consensus. The stock shows accelerating revenue growth, reaching $3.63B in 2025, but remains unprofitable with a net income margin of -23.79%. Recent news highlights AI Data Cloud traction and partnerships driving optimism, while cash flow from operations improved to $959.76M.
Outlook is positive due to AI-driven growth and consistent earnings beats, but high valuation (P/S 17.74) and persistent losses pose risks. Wall Street's $294.31 price target suggests ~12% upside, though competition and execution challenges require monitoring for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →
